Combining vaccines might give broader, longer-lasting immunity against the virus and new variants of it, and offer more flexibility to vaccine rollout.
Adults over 50 who have had a first dose of Pfizer or AstraZeneca can apply to take part in the Com-Cov study. BBC News
See also:
- Covid: South Africa variant surge probaby due to person travelling from Africa BBC News
- Covid-19: US agencies call for pause in Johnson & Johnson vaccine BBC News
- Weekly Covid deaths in England and Wales fall to lowest levels in six months The Daily Mail
- Anti-lockdown Sweden had highest rate of Covid-19 infections in Europe per capita last week The Daily Mail
- Moderna's vaccine is 90% effective at protecting against infection six months after the final dose The Daily Mail
- Mass Covid testing plans in disarray as pharmacies forced to ration supplies The Daily Telegraph
- As the UK inches towards normality, those with long Covid must not be forgotten | Frances Ryan The Guardian
- Covid vaccine side-effects: what are they, who gets them and why? The Guardian
- UK strategy of backing several Covid vaccines seems to be paying off The Guardian
- Boris Johnson: easing lockdown will increase Covid infections The Guardian
- NHS Covid app update blocked for breaking Apple and Google privacy rules on location data iNews
- Rate of people with Covid antibodies ‘levels off’ across most of UK The Independent
- Lockdown easing may need to be reversed if variant spreads rapidly, says government adviser The Independent
No comments:
Post a Comment